Monopar Therapeutics
(NASDAQ:MNPR)
$0.689
-0.048[-6.51%]
At close: Mar 28
$0.689
0[0.00%]
After Hours: 4:43PM EDT
Consensus Rating1
Buy
Highest Price Target1
$17.00
Lowest Price Target1
$17.00
Consensus Price Target1
$13.00

Monopar Therapeutics Stock (NASDAQ:MNPR), Analyst Ratings, Price Targets, Predictions

Monopar Therapeutics Inc has a consensus price target of $13, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Maxim Group on June 1, 2023, May 15, 2023, and March 29, 2023. With an average price target of $6.33 between HC Wainwright & Co., HC Wainwright & Co., and Maxim Group, there's an implied 819.21% upside for Monopar Therapeutics Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Feb
0
0
0
0
0
Jan
0
0
0
0
0
Dec 23
0
0
0
0
0
Nov 23
0
0
0
0
0
Oct 23
0
0
0
0
0
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Maxim Group
EF Hutton
Roth Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Monopar Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
06/01/2023MNPRBuy Now
Monopar Therapeutics
$0.692367.34%HC Wainwright & Co.
Sean Lee
→ $17Reiterates → BuyGet Alert
05/15/2023MNPRBuy Now
Monopar Therapeutics
$0.69190.28%HC Wainwright & Co.
Sean Lee
$6 → $2MaintainsBuyGet Alert
03/29/2023MNPRBuy Now
Monopar Therapeutics
$0.69Maxim Group
Jason McCarthy
DowngradeBuy → HoldGet Alert
03/28/2023MNPRBuy Now
Monopar Therapeutics
$0.692367.34%EF Hutton
Elemer Piros
$24 → $17MaintainsBuyGet Alert
03/24/2023MNPRBuy Now
Monopar Therapeutics
$0.693383.31%EF Hutton
Elemer Piros
→ $24Reiterates → BuyGet Alert
02/15/2023MNPRBuy Now
Monopar Therapeutics
$0.69770.83%HC Wainwright & Co.
Sean Lee
→ $6MaintainsBuyGet Alert
02/14/2023MNPRBuy Now
Monopar Therapeutics
$0.693383.31%EF Hutton
Elemer Piros
→ $24Reiterates → BuyGet Alert
01/23/2023MNPRBuy Now
Monopar Therapeutics
$0.693383.31%EF Hutton
Elemer Piros
→ $24Initiates → BuyGet Alert
12/09/2022MNPRBuy Now
Monopar Therapeutics
$0.692512.48%Roth Capital
Kumaraguru Raja
→ $18Reinstates → BuyGet Alert
08/16/2022MNPRBuy Now
Monopar Therapeutics
$0.69770.83%HC Wainwright & Co.
Sean Lee
$9 → $6MaintainsBuyGet Alert
11/01/2021MNPRBuy Now
Monopar Therapeutics
$0.691206.24%HC Wainwright & Co.
Sean Lee
Initiates → BuyGet Alert

FAQ

Q

What is the target price for Monopar Therapeutics (MNPR)?

A

The latest price target for Monopar Therapeutics (NASDAQ: MNPR) was reported by HC Wainwright & Co. on June 1, 2023. The analyst firm set a price target for $17.00 expecting MNPR to rise to within 12 months (a possible 2367.34% upside). 2 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Monopar Therapeutics (MNPR)?

A

The latest analyst rating for Monopar Therapeutics (NASDAQ: MNPR) was provided by HC Wainwright & Co., and Monopar Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Monopar Therapeutics (MNPR)?

A

There is no last upgrade for Monopar Therapeutics.

Q

When was the last downgrade for Monopar Therapeutics (MNPR)?

A

The last downgrade for Monopar Therapeutics Inc happened on March 29, 2023 when Maxim Group changed their price target from N/A to N/A for Monopar Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Monopar Therapeutics (MNPR)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monopar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monopar Therapeutics was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.

Q

Is the Analyst Rating Monopar Therapeutics (MNPR) correct?

A

While ratings are subjective and will change, the latest Monopar Therapeutics (MNPR) rating was a reiterated with a price target of $0.00 to $17.00. The current price Monopar Therapeutics (MNPR) is trading at is $0.69, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch